Renalytix Share Discussion Threads

[ny boy] 07/5/2019 11:51

Looks a good stock, I am in (STX) from early days, awaiting FDA decision 27 July, so happy to start investing here, could do with a little pull back though!

[wan] 07/5/2019 07:37

Today's news provides for further encouraging development, and underscores previous news flow regarding the ability to develop companion diagnostics, which in turn implies to me (at least), that the 'overall' offering from Renalytix is likely to be of increasing interest to drug developers.....cue my previous post 31!

[wan] 02/5/2019 07:34

The excellent rate of progress continues, as another key operational milestone is successfully delivered!

[pugugly] 26/4/2019 07:06

The Company is pleased to confirm that relevant EKF shareholders on the register as at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held. Entitlements will be rounded down to the nearest whole number of RENX Shares and fractional entitlements will be aggregated and sold in the open market with the net proceeds donated to charity, in line with the Company's articles.

[cambridgedon] 26/4/2019 06:22

Please can someone remind me of the basis for the issue of free shares in RENX as a proportion of ones holding in EKF at the time of the announcement. My allowance has suddenly arrived in my sipp without any detail to allow me to check it's accuracy.
Many thanks,
CD

[wilsonst1] 21/4/2019 20:42

Cheers Wan

[wan] 21/4/2019 07:35

Given the impending end of the lock-up period, this morning I caught up with some further Renalytix research. In particular the recent investor briefing/presentation and the recent CREDENCE trial results (funded by the pharmaceutical company Janssen who manufactures the Invokana) and the subsequent news flow.

Some thought provoking CREDENCE news flow -

Janssen Pharmaceuticals Diabetes Drug May Also Prevent, Slow Kidney Disease
15 April 2019


17 APRIL, 2019
A landmark clinical trial has provided “renewed optimism” for patients with type 2 diabetes and kidney disease, after researchers found a drug reduced the risk of renal failure by almost a third.



15th April 2019
Johnson & Johnson's diabetes drug Invokana has shown it can slow down kidney disease or even prevent it all together.

The results from the phase 3 CREDENCE study are an important boost for Invokana, which is trailing behind other competitors in the SGLT2 inhibitor class in terms of market share.

The trial puts Invokana one step ahead of rivals, such as AstraZeneca, the renal outcomes study for its SGLT2 drug Farxiga due in November 2020.

Meanwhile Sanofi and Lexicon's Zynquista and Eli Lilly and Boehringer Ingeheim's market leader Jardiance are also both in renal outcomes trials, with their respective results expected by 2022. It seems likely that the other drugs in the class will also prove their value in kidney disease - just as protection against heart disease has been proven in cardiovascular outcomes trials across the class.

Analysts expect Jardiance to maintain its lead in the field over this period, with Evaluate Pharma forecasting it will hit revenues of $3.51bn by 2024.

Full story -

As the above indicates, there are more trial outcomes to follow and a wall of money flowing into the potential treatment of kidney disease. However, without effective diagnostics, dare I suggest 'companion' diagnostics and thus effective management of kidney disease, the ultimate goal of 'effective' treatment will still be missed......cue RenalytixAI proposals!

I found the Investor briefing informative overall, and given the CREDENCE trial results and news flow, slides 24 and 25 particularly stood out.


Slide 24 -
Advanced Diagnostics + Novel Drug
Development = Personalized Medicine

We’ve done it in cancer

Now its time for the kidney

and slide 25 -

The age of personalized drug therapy for kidney is here
(SGLT2 Inhibitors)

[9degrees] 01/4/2019 09:52

tks wan for yr valuable input . v quiet thread so far but am sure it will warm up after 22 april when we can trade those transferred shares

[wan] 01/4/2019 07:53

Another very encouraging announcement today, details of which provides a notable stride towards validation of KidneyIntelX and certainly focuses attention on the previously initiates Clinical Validation Study (initiated in January), which if successful will provide for a significant value inflection point.

[wan] 25/3/2019 07:40

The inaugural interim results makes for interesting reading and details the excellent progress to date. They also detail the near/medium term operational milestones, which they appear confident about delivering upon and is very encouraging, especially as they envisage that they represent value inflection points.

Publication, in the coming days, of the results from a confirmation study will no doubt also make for encouraging reading.

[wan] 22/3/2019 07:44

Another encouraging update, with another impressive list of experts assembled, which sends a message regarding the need/opportunity and indeed the Renalytix technology offering/potential.

[wan] 12/3/2019 07:49

'Beyond' what we already know, it will be interesting to learn what the Investor Briefing will be communicating, but one would assume there may be more to tell.

[wan] 25/2/2019 07:51

An interesting read that puts some perspective on the level of interest and the rate of adoption in AI -

Partners Explores “Transformative” Realities of AI in Healthcare

At the World Medical Innovation Forum, Partners HealthCare will combine futurism with reality to explore the state of artificial intelligence in healthcare.

The three-day event usually focuses on a different theme every year. Past conferences have zeroed in on neurology, oncology, and cardiac care, exploring the intersection between diagnostics, best practices, analytics, and the financial strategies that make it all work.

In 2018, Partners shifted its gaze to artificial intelligence in healthcare, with the goal of breaking down the challenges and opportunities of machine learning to provide enhanced decision support to clinicians across the care continuum.

Normally, the 2019 edition of the WMIF would follow the pattern and move on to yet another area of focus.

But leaders at the health system made an atypical decision: to stick with artificial intelligence for another year so attendees could move even deeper into this complex, fascinating area of study.

“Typically, our Disruptive Dozen showcase looks at what’s coming in the next decade,” he said. “This year, we’re looking at what’s going to overhaul healthcare in the next 12 months. That’s how quickly AI is moving.”

Full article -

[wan] 13/2/2019 07:39

Worth a look, AKESOGEN -

Expert in the field of Genomics, AKESOgen provides premier research services and the highest quality data for scientists doing clinical or basic research across the world. Serving clients in biotech, pharmaceutical, academic and government research/testing, the company delivers data at the apex of quality, enhances clients’ productivity and enables them to meet important deadlines by offering the best in customer service and a collaborative, consultative relationship. Expertise, Advice, Consultation, Responsiveness and Unsurpassed Data Quality: AKESOgen is Your Research Partner.

[wan] 13/2/2019 07:33

Edited a few typo's!

[wan] 13/2/2019 07:29

A very encouraging development announced today, with an expansion and ratcheting up in both capacity and capabilities, capabilities which are beyond the initial focus on kidney disease.

In my book, Renalytix has just put a foot into a much larger space within the healthcare artificial intelligence market, especially in support of pharmaceutical companies looking to leverage off of the advantages of deploying AI. Furthermore, the ability to develop companion diagnostics, which in turn also helps to support pharma's drug authorisation and indeed which becomes an integral part, such that it is essential for the safe and effective use of a corresponding therapeutic product, obviously has great potential.

This sets Renalytix apart from even the likes Google's Deep Mind, and not in an insignificant way!

[wan] 06/2/2019 10:50

Another positive update indicates that we are firmly on schedule as per IPO and EKF's Investor Presentation.

[wan] 23/1/2019 07:32

Today's news is very encouraging in terms of the expanded study and the involvement of other parties, the scale and clinical breadth of which is indeed impressive.

It's also encouraging that the time table for commercial launch of the laboratory developed test appears to be on schedule.

Given that others are involved in this study, it implies that there is a lot of interest, which appears to bode well for Renalytix stated intention to enter into further collaborations beginning in 2019.

[wan] 09/1/2019 06:24

FDA accommodating to realise the reality that AI will indeed change healthcare -

January 08, 2019

By Jennifer Bresnick

FDA Tackles Artificial Intelligence with New Software Review Plan

The FDA is speeding up its regulatory processes to accommodate the new realities of the artificial intelligence ecosystem.

The FDA is moving quickly to ensure the development of a safe and effective artificial intelligence ecosystem in healthcare by releasing new documents intended to offer guidance to the health IT community.

The agency has published a new Software Precertification (Pre-Cert) Pilot Program working model test plan and a regulatory framework explaining how it plans to regulate the next generation of digital health devices.

The agency plans to exchange its traditional regulatory approaches for a model that offers more flexibility and faster, iterative review processes to accommodate the realities of the software development market and the fast-paced advancement of AI and machine learning.

During 2019, the FDA will test the new model’s effectiveness through the Pre-Cert Pilot Program.

“The goal of this phase of the pilot is to determine the contours of a possible regulatory model that provides efficient regulatory oversight of certain software-based medical devices from manufacturers who have demonstrated a robust culture of quality and organizational excellence (CQOE) and are committed to monitoring real-world performance while assuring that these devices are safe and effective,” the FDA explained.

“In developing Version 1.0 of the program, the current focus is to establish processes for software as medical device (SaMD) technologies, which may include software functions that use artificial intelligence and machine learning algorithms.”

The model would be implemented under the De Novo classification process, which is intended to create a speedy but thorough process for approving lower-risk medical devices.

Full story -

[wan] 06/1/2019 06:32

The following exemplifies and justifies Renalytix approach/entry into this underserved market, but it must surely serve as a serious reality check and wake-up call in the US! -

December 7th, 2018
Posted by Kristina Sauerwein-Washington University

The burden of chronic kidney disease, as well as the probability of death related to chronic kidney disease, have increased substantially over the past 15 years in all 50 US states, report researchers.
Such increases also were seen in younger adults ages 20 to 54, a group in which kidney disease had been uncommon. The findings appear in JAMA Network Open.

“It is particularly concerning that chronic kidney disease is becoming more common in younger people. This is a remarkable move in the wrong direction.”

“The decline is largely reflective of medical advances in cardiovascular disease and cancer treatment,” Al-Aly says. “Similarly, the increase in chronic kidney disease reflects a relative stagnation in new treatments. There have been no major advances to slow or reverse kidney disease during the past two decades.”

“Public health priorities, policy initiatives, funding allocation, and advocacy efforts need to catch up to this reality that the burden of chronic kidney disease is rising, and the speed of change now outpaces other noncommunicable diseases,” Al-Aly says. “A concerted effort should be made to put the brakes on this.”

Full article (including link to study) -

[wan] 03/1/2019 08:40

Thanks Charlie, I do now recall someone else saying the same just after the listing.

[charlieej] 03/1/2019 08:00

For info I bought through aj bell

[wan] 02/1/2019 11:02

9degrees...I assume that is indeed the case with regard to Barclays, but the shares are obviously available elsewhere. However, I am not sure if such sources would accommodate PI's.

[9degrees] 02/1/2019 10:53

How can Chris mills buy shares when Barclays smart investor says not available ?
Is this share not available to Pi's until 22 april ?